

THERIOPHARM

We develop drug delivery systems platforms for any administration route. We can potentially target any disease using our **NANOCOMBO** approach with **combines drug repurposing + multi-drug loading in one single nano-drop**.

Activities

Theripharm is an innovative pharmaceutical company dedicated to advancing drug delivery technologies and antimicrobial solutions, with a particular focus on combating antibiotic resistance and developing new cancer treatments. **The company leverages proprietary cyclodextrin derivatives, prebiotic oligosaccharides, and nanomedicine platforms to enhance drug efficacy and expand therapeutic possibilities.**

Theripharm's main activities center on the development of advanced drug delivery systems and antimicrobial products. Its core technologies include novel cyclodextrin derivatives and prebiotic oligosaccharides, which are integral to addressing antibiotic resistance and pioneering cancer therapies. The company's nanomedicine platform utilizes molecular encapsulation and the proprietary **THERIOSOME polymersome technology**, enabling versatile administration routes such as oral, intravenous, and intra-tumoral delivery. The THERIOSOME platform is built with pharmaceutical-grade, GRAS components and supports a wide range of drug delivery applications due to its optimal particle size (50–60 nm).

A key strategic axis is the **THERIOCID platform**, which targets hospital-acquired, multi- and pan-resistant pathogens like *Acinetobacter baumannii*, *Staphylococcus aureus*, and *Pseudomonas aeruginosa*. THERIOCID demonstrates broad-spectrum antimicrobial activity against over 250 pathogen species and has been validated in preclinical murine sepsis models. Notably, it employs a unique combination of three non-antibiotic molecules to address antibiotic resistance.

Theripharm also develops **Theriogels**—supramolecular and thermosensitive gels capable of delivering a variety of bioactive or food ingredients, including antimicrobials, antioxidants, and vitamins. On the commercialization front, products such as VIROKYL (gels, creams, sprays, wipes) are marketed under the HygiisPharma brand in France, meeting stringent European standards for viricidal, bactericidal, and fungicidal efficacy.

Strategically, Theripharm is committed to leveraging advanced materials science and nanotechnology to address urgent healthcare challenges, particularly antimicrobial resistance and effective drug delivery. Its platforms are validated through rigorous preclinical testing and are designed for broad therapeutic and preventive applications, including both hospital and consumer hygiene products.

WWW.THERIOPHARM.com